T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors

Similar Items

• Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
  od: Laksmi Wulandari, i dr.
  Izdano: (2018-07-01)
• Comparison of Detection of Epidermal Growth Factor Receptor (EFGR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients
  od: Wulandari, Laksmi, i dr.
  Izdano: (2020)
• The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
  od: Huang, Yen-Hsiang, i dr.
  Izdano: (2018)
• Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
  od: O’Kane, G.M., i dr.
  Izdano: (2018)
• Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors
  od: Jiang, Zhansheng, i dr.
  Izdano: (2018)